Pott's disease medical therapy

Jump to navigation Jump to search

Pott's disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pott's Disease from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pott's disease medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pott's disease medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pott's disease medical therapy

CDC on Pott's disease medical therapy

Pott's disease medical therapy in the news

Blogs on Pott's disease medical therapy

Directions to Hospitals Treating Pott's disease

Risk calculators and risk factors for Pott's disease medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Aravind Kuchkuntla, M.B.B.S[2]

Overview

Pott's disease is treated with antituberculous drugs, for a duration of 6 months to 9 months. Patients must be closely monitored to assess the response to therapy and compliance with medication.

Medical Therapy

Treatment must be initiated in all patients as early as possible and waiting for the culture results should not delay the treatment, Empiric therapy must be initiated in all patients. Treatment options and duration of therapy is controversial.[1]

Duration of Therapy

WHO Recommendations

American Thoracic Society Recommendations

British Thoracic Society Recommendations

Treatment Regimen

  • Intensive phase
    • Preferred regimen: Isoniazid 300 mg PO (5 mg/kg/day) qd for 8 weeks AND Rifampicin 600 mg PO (10 mg/kg/day) qd for 8 weeks AND Pyrazinamide 2 g PO (25 mg/kg/day) qd for 8 weeks AND Ethambutol 1.6 g PO (15 mg/kg/day) qd for 8 weeks
  • Continuation phase
    • Preferred regimen (1): Isoniazid 300 mg PO (5 mg/kg/day) qd AND Rifampicin 600 mg PO (10 mg/kg/day) qd for 18 weeks
    • Preferred regimen (2): Isoniazid 300 mg PO twice weekly (5 mg/kg/day) AND Rifampicin 600 mg/day PO twice weekly (10 mg/kg/day) for 18 weeks

Response to Treatment

Clinically, reduction in pain, improvement of neurological deficit and correction of spine deformity indicate response to treatment.[6]

References

  1. Kandwal P, G V, Jayaswal A (2016). "Management of Tuberculous Infection of the Spine". Asian Spine J. 10 (4): 792–800. doi:10.4184/asj.2016.10.4.792. PMC 4995267. PMID 27559464.
  2. "Communicable Diseases Module: 14. Diagnosis and Treatment of Tuberculosis".
  3. "Treatment of Tuberculosis American Thoracic Society, CDC, and Infectious Diseases Society of America".
  4. "Tuberculosis | recommendations | Guidance and guidelines | NICE".
  5. Prasad K, Singh MB, Ryan H (2016). "Corticosteroids for managing tuberculous meningitis". Cochrane Database Syst Rev. 4: CD002244. doi:10.1002/14651858.CD002244.pub4. PMC 4916936. PMID 27121755.
  6. Sharma A, Chhabra HS, Chabra T, Mahajan R, Batra S, Sangondimath G (2017). "Demographics of tuberculosis of spine and factors affecting neurological improvement in patients suffering from tuberculosis of spine: a retrospective analysis of 312 cases". Spinal Cord. 55 (1): 59–63. doi:10.1038/sc.2016.85. PMID 27241442.

Template:WH Template:WS